News about Global Pharma

FaceHeart Corporation Gets FDA 510(k) Clearance for FaceHeart Vitals

FaceHeart Corporation (FaceHeart), an AI health tech company, has received another FDA 510(k) clearance for FaceHeart Vitals™, its contactless video-based vital sign solution.

Global Pharma | 02/05/2025 | By Manvi |  602

Winter Park Chiropractor Introduces EXOMIND Brain Stimulation for Mental Health and Emotional Relief

Individuals suffering from depression, stress or mental fog can find relief at Winter Park Chiropractor, the office of Dr. Andrew Hull. This state-of-the-art chiropractic clinic is now offering EXOMIND, a cutting-edge treatment enhancing mental health and emotional regulation through non-invasive brain stimulation.

Global Pharma | 02/05/2025 | By Manvi |  324

S&E bio Secures Korea's First Approval for Exosome-Based Therapy Clinical Trial

S&E bio Co. Ltd. has received Korea's Ministry of Food and Drug Safety (MFDS) approval to begin Phase 1b clinical trial of an exosome-based therapy, SNE-101. The exosomes carry therapeutic microRNAs designed to enhance neuroregeneration.

Global Pharma | 02/05/2025 | By Manvi |  335

RoosterBio, Thermo Fisher Scientific Partner to Advance Cell and Exosome Therapy Manufacturing

RoosterBio has partnered with Thermo Fisher Scientific to accelerate the development and manufacturing of advanced cell and exosome therapies for degenerative diseases, combining hMSC expertise with GMP manufacturing capabilities.

Global Pharma | 02/05/2025 | By Manvi |  270

Gland Pharma Secures USFDA Approval for Latanoprostene Bunod Ophthalmic Solution

Gland Pharma has received USFDA approval for its generic version of Latanoprostene Bunod Ophthalmic Solution, 0.024 percent, securing first-to-file status with 180 days of generic drug exclusivity.

Global Pharma | 01/05/2025 | By Manvi |  501

Strides Pharma Secures USFDA Approval for Celecoxib Capsules

Strides Pharma has announced that its Singapore-based step-down subsidiary has received USFDA approval for Celecoxib Capsules (100 mg, 200 mg, and 400 mg), a generic equivalent of Celebrex, strengthening its presence in the anti-inflammatory segment.

Global Pharma | 01/05/2025 | By Manvi |  277

FDA-Approved Wegovy Now Easier to Access via Novo Nordisk's New Telehealth Initiative

In March 2025, Novo Nordisk launched NovoCare® Pharmacy to provide direct-to-patient, convenient home shipments of all dose strengths of Wegovy® at a reduced cost.

Global Pharma | 30/04/2025 | By Abha |  557

Zydus Secures Final Approval from USFDA for Niacin Extended-Release Tablets

Zydus Lifesciences has received final USFDA approval to manufacture Niacin Extended-Release Tablets in 500 mg, 750 mg, and 1,000 mg dosage, targeting cholesterol management and cardiovascular risk reduction.

Global Pharma | 30/04/2025 | By Abha |  561

Transneural Therapeutics Appoints Dr. Mark Demitrack as Chief Research and Development Officer

Dr. Demitrack is an accomplished, internationally recognised neuropsychiatrist with deep expertise in innovative clinical research and strategic business planning.

Global Pharma | 30/04/2025 | By Abha |  424

Navamedic Extends Imdur Distribution Agreement Until 2032

Imdur® (isosorbide mononitrate), is a prescription medication used to prevent angina pectoris due to heart disease.

Global Pharma | 30/04/2025 | By Abha |  573